Exagen, Ohio State Aiming at Blood Test for Earlier Fibromyalgia Diagnosis

Exagen, Ohio State Aiming at Blood Test for Earlier Fibromyalgia Diagnosis
Exagen entered into an exclusive worldwide license agreement with the Ohio State Innovation Foundation to develop and market a blood test that can distinguish fibromyalgia from other disorders, allowing for an earlier diagnosis. Fibromyalgia is the most frequent cause of chronic musculoskeletal pain in the U.S. Yet, current estimates indicate that as many as 12 million people with fibromyalgia may remain undiagnosed, the company stated. The lack of reliable biomarkers is a significant challenge for timely diagnosis and treatment of this disorder. In particular, fibromyalgia may be misdiagnosed as an autoimmune rheumatic disease due to the common presence of antibodies that attack tissues and cause autoimmunity. Researchers at The Ohio State University recently described molecular "fingerprints" unique to fibromyalgia, found using vibrational spectroscopy to analyze patients' bloods samples. Vibrational spectroscopy identifies molecules by measuring their vibrations when absorbing energy. Each type of chemical bond in a molecule vibrates at a unique frequenc
Subscribe or to access all post and page content.